(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Medison Pharma to distribute 'Myalepta' in Canada on Monday.
The AIM-traded firm said the agreement completed the multi-regional distribution deals with Medison, first announced in February, to distribute Myalepta, or metreleptin, and 'Lojuxta', or lomitapide, in Israel, and 'Juxtapid', or lomitapide in Canada.
"Today's announcement represents continued progress as we grow our commercial assets and expand access to treatment for patients in existing and new territories," said chief executive officer Dr Joe Wiley.
"We are also pleased to extend our engagement with Medison and further benefit from their expertise in Canada and other territories."
At 1140 GMT, shares in Amryt Pharma were down 0.49% in London at 204p.
11 Jan 2022 14:39
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York